Prominent Sponsors 33
Top Companies Participating in Acute Myelocytic Leukemia( AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials 35
Prominent Drugs 37
Latest Clinical Trials News on Acute Myelocytic Leukemia( AML, Acute Myeloblastic Leukemia) 39
Feb 23, 2017: Cyclacel Announces Top-Line Results From Pivotal Phase 3 SEAMLESS Study in Elderly Patients With Acute Myeloid Leukemia 39
Feb 23, 2017: Children’ s National Health System Experts Present Data on Novel Approach to Cell Therapy for Cancer Patients 40
Feb 17, 2017: Immune Pharmaceuticals Announces the launch of REMAIN, an international Overall Survival study with Ceplene and low dose Proleukin in REmission MAINtenance in Acute Myeloid Leukemia 40
Feb 13, 2017: Actinium Pharmaceuticals Presents Data On Actimab-A At BIO CEO & Investor Conference 41
Feb 06, 2017: FDA Grants Cellectis IND Approval to Proceed with the Clinical Development of UCART123, the First Gene Edited Off-the-Shelf CAR T-Cell Product Candidate developed in the U. S. 41
Feb 06, 2017: INNATE PHARMA announces top-line results from EffiKIR trial evaluating the efficacy of lirilumab 41
Feb 02, 2017: Trillium Therapeutics Provides Update On TTI-622 42
Jan 11, 2017: Regenacy Pharma ' s HDAC1 Inhibitor ACY-957 Demonstrates Potent Anti-Leukemic Activities 42
Jan 11, 2017: Regenacy Pharma ' s HDAC2 Inhibitor ACY-1035 Demonstrates Potent Anti-Leukemic Activities 43
Jan 09, 2017: Syros Pharma Outlines 2017 Strategic Goals, Provides Update On SY-1425 43 Jan 05, 2017: Mirati Therapeutics Provides Update On Cancer Pre-Clinical Program 44
Jan 03, 2017: Cellectis Submits IND Application for UCART123, an Allogeneic Gene Edited CAR T- Cell Product Candidate, in AML and BPDCN 44
Dec 28, 2016: argenx announces publication of seminal data supporting the therapeutic potential of ARGX-110 for acute myeloid leukemia in the Journal of Experimental Medicine 45
Dec 27, 2016: Seattle Genetics Announces Clinical Hold on Several Phase 1 Trials of Vadastuximab Talirine( SGN-CD33A) 45